Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Weak
Earnings
Very Weak
Growth
Earnings
Very Weak
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
61.3.9349.4906
Address
Suite 4 Level 14 350 Collins Street Melbourne, Victoria (VIC) 3000
Description
Alterity Therapeutics Ltd. is a clinical stage biotechnology company. It engages in the business of research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer's, Huntington, Parkinson’s, and other neurological disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.0 - 0.02
Trade Value (12mth)
AU$36,452.00
1 week
0%
1 month
0%
YTD
-11.11%
1 year
33.33%
All time high
1.50
EPS 3 yr Growth
-42.20%
EBITDA Margin
N/A
Operating Cashflow
-$13m
Free Cash Flow Return
-68.60%
ROIC
-104.00%
Interest Coverage
N/A
Quick Ratio
3.50
Shares on Issue (Fully Dilluted)
5313m
HALO Sector
Healthcare
Next Company Report Date
28-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
30 April 25 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
29 April 25 |
Change of Director's Interest Notice x 3
×
Change of Director's Interest Notice x 3 |
28 April 25 |
Alterity Phase 2 Presentation at MSA Symposium 2025
×
Alterity Phase 2 Presentation at MSA Symposium 2025 |
22 April 25 |
Updated Corporate Presentation
×
Updated Corporate Presentation |
22 April 25 |
Application for quotation of securities - ATH
×
Application for quotation of securities - ATH |
22 April 25 |
New Options - Top 20 Holders and Range of Units
×
New Options - Top 20 Holders and Range of Units |
17 April 25 |
Options Prospectus
×
Options Prospectus |
10 April 25 |
Alterity Presents Encouraging New Phase 2 Data in MSA
×
Alterity Presents Encouraging New Phase 2 Data in MSA |
10 April 25 |
Alterity Phase 2 Presentation at AAN 2025
×
Alterity Phase 2 Presentation at AAN 2025 |
09 April 25 |
Change of Director's Interest Notice x 3
×
Change of Director's Interest Notice x 3 |
08 April 25 |
Change in substantial holding
×
Change in substantial holding |
08 April 25 |
Becoming a substantial holder
×
Becoming a substantial holder |
07 April 25 |
Application for quotation of securities - ATH
×
Application for quotation of securities - ATH |
07 April 25 |
Notice Under Section 708A
×
Notice Under Section 708A |
07 April 25 |
Completion of Placement
×
Completion of Placement |
03 April 25 |
Alterity to Deliver Oral Presentation of ATH434 Trial at AAN
×
Alterity to Deliver Oral Presentation of ATH434 Trial at AAN |
31 March 25 |
Results of Meeting
×
Results of Meeting |
27 March 25 |
Alterity Completes Last Patient Visit in Open-Label Trial
×
Alterity Completes Last Patient Visit in Open-Label Trial |
24 March 25 |
Ceasing to be a substantial holder
×
Ceasing to be a substantial holder |
14 March 25 |
Application for quotation of securities - ATH
×
Application for quotation of securities - ATH |
13 March 25 |
Becoming a substantial holder
×
Becoming a substantial holder |
28 February 25 |
Half Yearly Report and Accounts
×
Half Yearly Report and Accounts |
28 February 25 |
Notice of Extraordinary General Meeting/Proxy Form
×
Notice of Extraordinary General Meeting/Proxy Form |
24 February 25 |
Proposed issue of securities - ATH
×
Proposed issue of securities - ATH |
19 February 25 |
Change in substantial holding
×
Change in substantial holding |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.